BOSTON - Mark D. Chalek has been named to the newly created post of Chief, Business Ventures for Beth Israel Deaconess Medical Center, where he will identify and pursue opportunities throughout the institution for business development and strategic alliances, and oversee intellectual property, technology commercialization and research collaborations with industry. Chalek has directed BIDMC's Office of Corporate Research since 1998.
"Mark has built and led BIDMC's now nationally recognized offices for intellectual property and technology transfer," said Paul F. Levy, President and CEO. "As a result, numerous biomedical products that help patients worldwide are now in the marketplace, and license revenues to BIDMC have increased ten-fold."
Chalek, of Brookline, has more than 20 years of executive experience in the health care and biotechnology industries, including four years as vice president of the Massachusetts Biotechnical Research Institute, a biomedical business incubator and venture capital company. In 1995, he founded MBI/Boston Biotechnology Innovation Center, which has served as a catalyst for the development of many new biomedical companies, including Cytologix, Eligix, Tolerance Pharmaceuticals and Centagenetix.
He was a founding executive director of the Boston Area Health Education Center and a faculty member of the Boston University School of Medicine and the University of Massachusetts Medical School. He also served as deputy commissioner of Boston's Department of Health and Hospitals.
In his expanded role, Chalek will develop and oversee plans to maximize revenue to BIDMC from the research enterprise; lead the institution's efforts in ancillary business development and strategic alliances; help develop a strategic plan for investments in research; and work with the development office to create and implement an overall plan for ongoing research philanthropy.